CA3180509A1 - Formulation comprising daprodustat - Google Patents
Formulation comprising daprodustat Download PDFInfo
- Publication number
- CA3180509A1 CA3180509A1 CA3180509A CA3180509A CA3180509A1 CA 3180509 A1 CA3180509 A1 CA 3180509A1 CA 3180509 A CA3180509 A CA 3180509A CA 3180509 A CA3180509 A CA 3180509A CA 3180509 A1 CA3180509 A1 CA 3180509A1
- Authority
- CA
- Canada
- Prior art keywords
- tablet
- immediate release
- release tablet
- dose
- daprodustat
- Prior art date
- Legal status (The legal status is an assumption and is not a legal conclusion. Google has not performed a legal analysis and makes no representation as to the accuracy of the status listed.)
- Pending
Links
Classifications
-
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
- A61K9/00—Medicinal preparations characterised by special physical form
- A61K9/20—Pills, tablets, discs, rods
- A61K9/2072—Pills, tablets, discs, rods characterised by shape, structure or size; Tablets with holes, special break lines or identification marks; Partially coated tablets; Disintegrating flat shaped forms
- A61K9/2077—Tablets comprising drug-containing microparticles in a substantial amount of supporting matrix; Multiparticulate tablets
-
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
- A61K31/00—Medicinal preparations containing organic active ingredients
- A61K31/33—Heterocyclic compounds
- A61K31/395—Heterocyclic compounds having nitrogen as a ring hetero atom, e.g. guanethidine or rifamycins
- A61K31/495—Heterocyclic compounds having nitrogen as a ring hetero atom, e.g. guanethidine or rifamycins having six-membered rings with two or more nitrogen atoms as the only ring heteroatoms, e.g. piperazine or tetrazines
- A61K31/505—Pyrimidines; Hydrogenated pyrimidines, e.g. trimethoprim
- A61K31/513—Pyrimidines; Hydrogenated pyrimidines, e.g. trimethoprim having oxo groups directly attached to the heterocyclic ring, e.g. cytosine
- A61K31/515—Barbituric acids; Derivatives thereof, e.g. sodium pentobarbital
-
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
- A61K45/00—Medicinal preparations containing active ingredients not provided for in groups A61K31/00 - A61K41/00
- A61K45/06—Mixtures of active ingredients without chemical characterisation, e.g. antiphlogistics and cardiaca
-
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
- A61K9/00—Medicinal preparations characterised by special physical form
- A61K9/20—Pills, tablets, discs, rods
- A61K9/2004—Excipients; Inactive ingredients
- A61K9/2009—Inorganic compounds
-
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
- A61K9/00—Medicinal preparations characterised by special physical form
- A61K9/20—Pills, tablets, discs, rods
- A61K9/2004—Excipients; Inactive ingredients
- A61K9/2013—Organic compounds, e.g. phospholipids, fats
- A61K9/2018—Sugars, or sugar alcohols, e.g. lactose, mannitol; Derivatives thereof, e.g. polysorbates
-
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
- A61K9/00—Medicinal preparations characterised by special physical form
- A61K9/20—Pills, tablets, discs, rods
- A61K9/2004—Excipients; Inactive ingredients
- A61K9/2022—Organic macromolecular compounds
- A61K9/205—Polysaccharides, e.g. alginate, gums; Cyclodextrin
- A61K9/2054—Cellulose; Cellulose derivatives, e.g. hydroxypropyl methylcellulose
-
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
- A61P7/00—Drugs for disorders of the blood or the extracellular fluid
- A61P7/06—Antianaemics
Landscapes
- Health & Medical Sciences (AREA)
- Life Sciences & Earth Sciences (AREA)
- Chemical & Material Sciences (AREA)
- Veterinary Medicine (AREA)
- Public Health (AREA)
- Medicinal Chemistry (AREA)
- General Health & Medical Sciences (AREA)
- Animal Behavior & Ethology (AREA)
- Pharmacology & Pharmacy (AREA)
- Epidemiology (AREA)
- Engineering & Computer Science (AREA)
- Bioinformatics & Cheminformatics (AREA)
- Biophysics (AREA)
- Molecular Biology (AREA)
- Inorganic Chemistry (AREA)
- Organic Chemistry (AREA)
- Nuclear Medicine, Radiotherapy & Molecular Imaging (AREA)
- General Chemical & Material Sciences (AREA)
- Chemical Kinetics & Catalysis (AREA)
- Hematology (AREA)
- Diabetes (AREA)
- Pharmaceuticals Containing Other Organic And Inorganic Compounds (AREA)
- Acyclic And Carbocyclic Compounds In Medicinal Compositions (AREA)
- Medicinal Preparation (AREA)
Applications Claiming Priority (5)
| Application Number | Priority Date | Filing Date | Title |
|---|---|---|---|
| US202063041403P | 2020-06-19 | 2020-06-19 | |
| US63/041,403 | 2020-06-19 | ||
| US202063043292P | 2020-06-24 | 2020-06-24 | |
| US63/043,292 | 2020-06-24 | ||
| PCT/EP2021/066386 WO2021255159A1 (en) | 2020-06-19 | 2021-06-17 | Formulation comprising daprodustat |
Publications (1)
| Publication Number | Publication Date |
|---|---|
| CA3180509A1 true CA3180509A1 (en) | 2021-12-23 |
Family
ID=76730508
Family Applications (1)
| Application Number | Title | Priority Date | Filing Date |
|---|---|---|---|
| CA3180509A Pending CA3180509A1 (en) | 2020-06-19 | 2021-06-17 | Formulation comprising daprodustat |
Country Status (7)
| Country | Link |
|---|---|
| US (1) | US20230225977A1 (cg-RX-API-DMAC7.html) |
| EP (1) | EP4167967A1 (cg-RX-API-DMAC7.html) |
| JP (1) | JP7797425B2 (cg-RX-API-DMAC7.html) |
| CN (1) | CN115697307A (cg-RX-API-DMAC7.html) |
| BR (1) | BR112022024533A2 (cg-RX-API-DMAC7.html) |
| CA (1) | CA3180509A1 (cg-RX-API-DMAC7.html) |
| WO (1) | WO2021255159A1 (cg-RX-API-DMAC7.html) |
Families Citing this family (3)
| Publication number | Priority date | Publication date | Assignee | Title |
|---|---|---|---|---|
| US20240228443A1 (en) * | 2021-06-18 | 2024-07-11 | Glaxosmithkline Intellectual Property (No.2) Limited | Novel manufacturing method of daprodustat and precursors thereof |
| WO2024257063A1 (en) * | 2023-06-16 | 2024-12-19 | Glenmark Life Sciences Limited | Solid dispersion of daprodustat and a process for the preparation thereof |
| KR20260061246A (ko) * | 2023-10-24 | 2026-05-06 | 카인드 파마슈티컬 | 저산소증 유도인자-프로릴히드록시라제 억제제를 함유하는 장시간 작용형 경구 의약품 및 그 사용 |
Family Cites Families (11)
| Publication number | Priority date | Publication date | Assignee | Title |
|---|---|---|---|---|
| TWI394747B (zh) | 2006-06-23 | 2013-05-01 | Smithkline Beecham Corp | 脯胺醯基羥化酶抑制劑 |
| CN101773498B (zh) * | 2009-12-30 | 2012-06-20 | 青岛黄海制药有限责任公司 | 一种含有非布司他的口服缓控释制剂的制备方法 |
| NZ735973A (en) * | 2015-04-01 | 2023-06-30 | Akebia Therapeutics Inc | Compositions and methods for treating anemia |
| TWI804919B (zh) * | 2015-06-30 | 2023-06-11 | 美商建南德克公司 | 含藥物之立即釋放錠劑及形成該錠劑的方法 |
| RU2736941C2 (ru) * | 2015-12-02 | 2020-11-23 | Мерк Шарп энд Доум Корп. | Фармацевтические композиции, содержащие доравирин, тенофовира дизопроксила фумарат и ламивудин |
| CA2937365C (en) * | 2016-03-29 | 2018-09-18 | F. Hoffmann-La Roche Ag | Granulate formulation of 5-methyl-1-phenyl-2-(1h)-pyridone and method of making the same |
| PH12018000227B1 (en) * | 2017-09-05 | 2019-03-11 | Frimline Private Ltd | A pharmaceutical composition for improving or preventing progression of chronic kidney disease |
| AU2018330994A1 (en) * | 2017-09-15 | 2020-04-16 | GlaxoSmithKline Intellectual Property (No. 2) Limited, England | Crystalline forms of gsk1278863, preparation method and pharmaceutical use thereof |
| CN111278433A (zh) * | 2017-09-26 | 2020-06-12 | 特沙诺有限公司 | 尼拉帕尼制剂 |
| CN112955130A (zh) * | 2018-10-30 | 2021-06-11 | 佩洛通治疗公司 | 包含取代茚满的固体分散体和药物组合物及其制备和使用方法 |
| EP3880663A1 (en) * | 2018-11-15 | 2021-09-22 | Teva Pharmaceuticals International GmbH | Solid state forms of daprodustat and process for preparation thereof |
-
2021
- 2021-06-17 CN CN202180043608.0A patent/CN115697307A/zh active Pending
- 2021-06-17 CA CA3180509A patent/CA3180509A1/en active Pending
- 2021-06-17 EP EP21736531.1A patent/EP4167967A1/en active Pending
- 2021-06-17 BR BR112022024533A patent/BR112022024533A2/pt not_active Application Discontinuation
- 2021-06-17 WO PCT/EP2021/066386 patent/WO2021255159A1/en not_active Ceased
- 2021-06-17 JP JP2022577794A patent/JP7797425B2/ja active Active
- 2021-06-17 US US18/010,245 patent/US20230225977A1/en active Pending
Also Published As
| Publication number | Publication date |
|---|---|
| WO2021255159A1 (en) | 2021-12-23 |
| EP4167967A1 (en) | 2023-04-26 |
| JP2023532223A (ja) | 2023-07-27 |
| JP7797425B2 (ja) | 2026-01-13 |
| US20230225977A1 (en) | 2023-07-20 |
| BR112022024533A2 (pt) | 2022-12-27 |
| CN115697307A (zh) | 2023-02-03 |
Similar Documents
| Publication | Publication Date | Title |
|---|---|---|
| KR100645866B1 (ko) | 발데콕시브 조성물 | |
| JP4084309B2 (ja) | 単一の結晶形を含有する固形製剤 | |
| US20230225977A1 (en) | Formulation comprising daprodustat | |
| CA2662265A1 (en) | Imatinib compositions | |
| TWI903066B (zh) | 包含1-(3-氰基-1-異丙基-吲哚-5-基)吡唑-4-羧酸之口服用複合調配物 | |
| EP4048276B1 (en) | Solid pharmaceutical formulations comprising ticagrelor | |
| EP4058025A1 (en) | Pharmaceutical compositions comprising ticagrelor | |
| JP7618806B2 (ja) | 1-(3-シアノ-1-イソプロピル-インドール-5-イル)ピラゾール-4-カルボン酸を含む経口用製剤、およびその製造方法 | |
| JP2021518422A (ja) | レナリドミドを含む医薬組成物 | |
| Parikh et al. | Formulation optimization and evaluation of immediate release tablet of telmisartan | |
| WO2019012552A4 (en) | Compositions of ferric organic compounds | |
| KR20180060705A (ko) | 에제티미브 및 로수바스타틴을 포함하는 경구용 복합정제 | |
| WO2022115055A1 (en) | Immediate release composition of favipiravir | |
| WO2021117697A1 (ja) | 固形製剤 | |
| KR102330953B1 (ko) | 소듐-1-[6-(모르폴린-4-일)피리미딘-4-일]-4-(1h-1,2,3-트리아졸-1-일)-1h-피라졸-5-올레이트를 함유하는 제약 투여 형태 | |
| RU2321405C2 (ru) | Лекарственное средство, обладающее анальгезирующим, жаропонижающим и психостимулирующим действием, и способ его получения | |
| CA2609026A1 (en) | Formulations containing losartan and/or its salts | |
| EP4342458A1 (en) | Oral formulation containing 1-(3-cyano-1-isopropyl-indol-5-yl)pyrazole-4-carboxylic acid | |
| WO2024128996A1 (en) | Monolayer tablet composition of empagliflozin and metformin hydrochloride | |
| WO2024225996A1 (en) | A new pharmaceutical tablet composition comprising eltrombopag olamine | |
| TR2023006078T2 (tr) | Favi̇pi̇ravi̇ri̇n hemen salimli kompozi̇syonu | |
| WO2022263899A1 (en) | Novel manufacturing method of daprodustat and precursors thereof | |
| EA049988B1 (ru) | Лекарственная форма для перорального применения, содержащая 1-(3-циано-1-изопропил-индол-5-ил)пиразол-4-карбоновую кислоту | |
| EP4213937A1 (en) | Solid dosage form comprising sitagliptin and method of preparation thereof | |
| EA051116B1 (ru) | Состав, содержащий цераласертиб |
Legal Events
| Date | Code | Title | Description |
|---|---|---|---|
| W00 | Other event occurred |
Free format text: ST27 STATUS EVENT CODE: A-1-1-W10-W00-W100 (AS PROVIDED BY THE NATIONAL OFFICE); EVENT TEXT: LETTER SENT Effective date: 20251222 |
|
| W00 | Other event occurred |
Free format text: ST27 STATUS EVENT CODE: A-1-1-W10-W00-W100 (AS PROVIDED BY THE NATIONAL OFFICE); EVENT TEXT: LETTER SENT Effective date: 20260204 |
|
| U13 | Renewal or maintenance fee not paid |
Free format text: ST27 STATUS EVENT CODE: N-1-6-U10-U13-U300 (AS PROVIDED BY THE NATIONAL OFFICE); EVENT TEXT: DEEMED ABANDONED - FAILURE TO RESPOND TO MAINTENANCE FEE NOTICE Effective date: 20260223 |
|
| B12 | Application deemed to be withdrawn, abandoned or lapsed |
Free format text: ST27 STATUS EVENT CODE: N-6-6-B10-B12-B301 (AS PROVIDED BY THE NATIONAL OFFICE); EVENT TEXT: DEEMED ABANDONED - FAILURE TO RESPOND TO A REQUEST FOR EXAMINATION NOTICE Effective date: 20260407 |
|
| W00 | Other event occurred |
Free format text: ST27 STATUS EVENT CODE: N-6-6-W10-W00-W100 (AS PROVIDED BY THE NATIONAL OFFICE); EVENT TEXT: LETTER SENT Effective date: 20260709 |
|
| W00 | Other event occurred |
Free format text: ST27 STATUS EVENT CODE: N-6-6-W10-W00-W100 (AS PROVIDED BY THE NATIONAL OFFICE); EVENT TEXT: LETTER SENT Effective date: 20260804 |